Show simple item record

dc.contributor.authorPolok, Kamil
dc.contributor.authorFronczek, Jakub
dc.contributor.authorArtigas, Antonio
dc.contributor.authorFlaatten, Hans Kristian
dc.contributor.authorGuidet, Bertrand
dc.contributor.authorDe Lange, Dylan W.
dc.contributor.authorFjølner, Jesper
dc.contributor.authorLeaver, Susannah
dc.contributor.authorBeil, Michael
dc.contributor.authorSviri, Sigal
dc.contributor.authorBruno, Raphael Romano
dc.contributor.authorWernly, Bernhard
dc.contributor.authorBollen Pinto, Bernardo
dc.contributor.authorSchefold, Joerg C.
dc.contributor.authorStudzińska, Dorota
dc.contributor.authorJoannidis, Michael
dc.contributor.authorOeyen, Sandra
dc.contributor.authorMarsh, Brian
dc.contributor.authorAndersen, Finn Husøy
dc.contributor.authorMoreno, Rui
dc.contributor.authorCecconi, Maurizio
dc.contributor.authorJung, Christian
dc.contributor.authorSzczeklik, Wojciech
dc.description.abstractBackground Noninvasive ventilation (NIV) is a promising alternative to invasive mechanical ventilation (IMV) with a particular importance amidst the shortage of intensive care unit (ICU) beds during the COVID-19 pandemic. We aimed to evaluate the use of NIV in Europe and factors associated with outcomes of patients treated with NIV. Methods This is a substudy of COVIP study—an international prospective observational study enrolling patients aged ≥ 70 years with confirmed COVID-19 treated in ICU. We enrolled patients in 156 ICUs across 15 European countries between March 2020 and April 2021.The primary endpoint was 30-day mortality. Results Cohort included 3074 patients, most of whom were male (2197/3074, 71.4%) at the mean age of 75.7 years (SD 4.6). NIV frequency was 25.7% and varied from 1.1 to 62.0% between participating countries. Primary NIV failure, defined as need for endotracheal intubation or death within 30 days since ICU admission, occurred in 470/629 (74.7%) of patients. Factors associated with increased NIV failure risk were higher Sequential Organ Failure Assessment (SOFA) score (OR 3.73, 95% CI 2.36–5.90) and Clinical Frailty Scale (CFS) on admission (OR 1.46, 95% CI 1.06–2.00). Patients initially treated with NIV (n = 630) lived for 1.36 fewer days (95% CI − 2.27 to − 0.46 days) compared to primary IMV group (n = 1876). Conclusions Frequency of NIV use varies across European countries. Higher severity of illness and more severe frailty were associated with a risk of NIV failure among critically ill older adults with COVID-19. Primary IMV was associated with better outcomes than primary NIV.en_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.titleNoninvasive ventilation in COVID-19 patients aged ≥ 70 years—a prospective multicentre cohort studyen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.rights.holderCopyright 2022 The Author(s)en_US
dc.source.journalCritical Careen_US
dc.identifier.citationCritical Care. 2022, 26, 224.en_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal